These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7624265)

  • 1. The risk of sulfasalazine- and mesalazine-associated blood disorders.
    Jick H; Myers MW; Dean AD
    Pharmacotherapy; 1995; 15(2):176-81. PubMed ID: 7624265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous hypersensitivity reaction to mesalazine.
    Aparicio J; Carnicer F; Girona E; Gmez A
    Am J Gastroenterol; 1996 Mar; 91(3):620-1. PubMed ID: 8633534
    [No Abstract]   [Full Text] [Related]  

  • 3. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.
    Turunen U; Elomaa I; Anttila VJ; Seppälä K
    Scand J Gastroenterol; 1987 Sep; 22(7):798-802. PubMed ID: 2890198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.
    Masuda H; Takahashi Y; Nishida Y; Asai S
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1549-55. PubMed ID: 22546896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
    Ransford RA; Langman MJ
    Gut; 2002 Oct; 51(4):536-9. PubMed ID: 12235076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
    Van Staa TP; Travis S; Leufkens HG; Logan RF
    Gastroenterology; 2004 Jun; 126(7):1733-9. PubMed ID: 15188168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
    Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
    Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [5-aminosalicylic acid and chronic inflammatory bowel diseases in children].
    Klotz U
    Klin Padiatr; 1995; 207(5):285-7. PubMed ID: 7500605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adverse effects of sulfasalazine: discussion of mechanism and role of sulfonamide structure].
    Atheymen R; Affes H; Ksouda K; Mnif L; Sahnoun Z; Tahri N; Zeghal KM; Hammami S
    Therapie; 2013; 68(6):369-73. PubMed ID: 24356188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome.
    Tebano MT; Traversa G; Da Cas R; Loizzo A
    Aliment Pharmacol Ther; 1996 Aug; 10(4):659-63. PubMed ID: 8853773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfasalazine, 5-ASA and acute pancreatitis in crohn's disease.
    Debongnie JC; Dekoninck X
    J Clin Gastroenterol; 1994 Dec; 19(4):348-9. PubMed ID: 7876525
    [No Abstract]   [Full Text] [Related]  

  • 12. [Leukopenia in a patient successively treated with sulfasalazine and mesalazine].
    Bodin F; Biour M; Grange JD
    Therapie; 1991; 46(4):341. PubMed ID: 1683025
    [No Abstract]   [Full Text] [Related]  

  • 13. Mesalazine during pregnancy.
    Marteau P; Devaux CB
    Lancet; 1994 Dec; 344(8938):1708-9. PubMed ID: 7996988
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalazine is safe for the treatment of IBD.
    D'Haens G; van Bodegraven AA
    Gut; 2004 Jan; 53(1):155. PubMed ID: 14684596
    [No Abstract]   [Full Text] [Related]  

  • 16. [Salicylic derivatives in the clinical treatment of inflammatory bowel disease: new perspectives].
    Damião AO; Sipahi AM
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):271-8. PubMed ID: 2576896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic inflammatory intestinal disease and nephritis].
    Behrens R; Ruder H
    Klin Padiatr; 1992; 204(1):61-4. PubMed ID: 1346814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.
    Linares V; Alonso V; Domingo JL
    Expert Opin Drug Saf; 2011 Mar; 10(2):253-63. PubMed ID: 21219240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experiences with phase III studies in the area of gastroenterology].
    Kruis W
    Verh Dtsch Ges Inn Med; 1991; 97():503-6. PubMed ID: 1687301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.